

# Little Guides Pediatric Melanocytic Lesion Choices

BY BETSY BATES  
Los Angeles Bureau

MONTEREY, CALIF. — Melanocytic tumors of unknown malignant potential represent some of the most difficult cases in pediatric dermatology, since little agreement exists about their diagnostic criteria, management, or outcome.

"They cause everyone, including pathologists, referring dermatologists, and surgeons, to lose sleep," said Dr. Susan Swetter, director of Stanford (Calif.) University's pigmented lesion and cutaneous melanoma clinic, at the annual meeting of the California Society of Dermatology and Dermatologic Surgery.

Dr. Swetter described the management of an 8-mm raised, blue-black nodule that appeared behind the right ear of an 11-year-old girl. Satellite blue-black macules appeared on the periphery of the lesion.

A partial 5-mm punch biopsy was reviewed by pathologists at Stanford; the University of California, San Francisco; and Massachusetts General Hospital, Boston. The conclusion was that the lesion was a melanocytic tumor of unknown malignant potential (MELTUMP) with decidedly mixed signals: no ulceration but a relatively high mitotic rate (4/mm<sup>2</sup>) and probable angiolymphatic invasion.

Differential diagnoses included a pigmented epithelioid melanocytoma, an agminated Spitz nevus, or a "low-grade" melanoma (Clark's level III, Breslow thickness 3.7 mm).

The patient underwent a "fairly intuitive" comprehensive work-up, including a thorough personal and family history, a review of the timing and speed of growth of the lesion, and a total body skin examination and physical examination, including palpation of regional lymph node basins to assess for metastasis.

Melanoma experts agree that MELTUMP lesions should be completely excised, but the specifics about recommended margins remain hazy, Dr. Swetter explained. Some experts would decide to perform a wide excision in such a case, perhaps including sentinel lymph node biopsy, as if they were treating a melanoma.

At Stanford, where the patient was seen, the decision was made to take a 1-cm margin, narrower than the 2-cm margin that would be appropriate for a 3.7-mm melanoma, and to await the pathology results before deciding whether to perform a sentinel lymph node biopsy or lymph node dissection.

The histology on the wide excision specimen showed that the lesion was symmetrical and well circumscribed with a polypoid proliferation of darkly pigmented melanocytes and a mitotic rate "well below 1/mm<sup>2</sup>."

Dr. Swetter described the applicable histology images as revealing "deeply pigmented epithelial spindle cells and unmistakable angiolymphatic invasion." "Our pathologists thought this was most consistent with a melanocytoma diagnosis," and noted its rarity as well as its "uncertain biological behavior," said Dr. Swetter.

A comparative genomic hybridization study was ordered from the UCSF labo-

ratory, but results were estimated to take 6-8 weeks, a period of time that could compromise afferent lymphatic drainage from a scalp lesion and reduce the accuracy of the sentinel node biopsy.

After extensive discussions with the child's parents, the Stanford team elected to perform a sentinel lymph node biopsy but to await the outcome of the comparative genomic hybridization studies prior to performing complete lymph node dissection in the event that the sentinel node

specimen was positive. A metastatic work-up with PET/CT scanning was performed "in part ... to allay some of the parental concern about metastatic disease." Parenthetically, Dr. Swetter noted that such a scan would not generally be indicated in an asymptomatic patient with no signs of metastatic disease and would not preclude the possibility of a positive sentinel node biopsy. The scans were negative.

Two sentinel lymph nodes were identified and removed in the right cervical

neck. One was positive for subcapsular and parenchymal metastatic foci of pigmented epithelioid melanocytoma and stained strongly positive for S100, MelanA, and HMB45. MELTUMP lesions have been associated with a very high rate of sentinel lymph node positivity in the two largest retrospective studies to date (44%-50%, compared with about 20% for typical melanomas with Breslow thickness greater than 1 mm.)

However, the picture is confusing, be-

**NONSCHEDULED ROZEREM—**  
**ZERO**  
**EVIDENCE OF ABUSE OR DEPENDENCE**

**\*Rozerem<sup>TM</sup> (ramelteon) is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use.**

**Important safety information**  
Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

**Please see adjacent Brief Summary of Prescribing Information.**

cause studies also associate atypical Spitz tumors with a very high survival rate despite apparent micrometastases.

"The question is, What is the clinical significance [of the high rate of positive sentinel lymph nodes in these tumors]? Does it imply a fatal outcome?" she asked.

In the case of Dr. Swetter's patient, a comparative genomic hybridization offered what appeared to be optimistic information, since the lesion contained aberrations on chromosome 11, a finding that has been exclusively associated with Spitz nevi in comparative studies with other benign nevi and melanomas. The patient has been followed clinically for more than a

year without evidence of recurrent disease.

Much uncertainty exists around the management of MELTUMPs; which are characterized by a lack of agreement among pathologists, even those specializing in melanoma pathology.

The lesions should be completely excised, and treated similarly to melanomas when they are characterized by frank atypia or uncertain biologic behavior.

Until more data can be gathered from the national pediatric melanoma and melanocytic neoplasms, Dr. Swetter urged frank discussions among medical professionals and families about the diagnostic uncertainty regarding these lesions. ■



STANFORD UNIVERSITY, DEPARTMENTS OF DERMATOLOGY AND PATHOLOGY, AND THE MELANOMA CARE COALITION, PHARMADURA, LLC

The melanocytic tumor of unknown malignant potential on the 11-year-old girl is shown here.

## You can prescribe Rozerem for as long as you need to\*

Clinical studies show no evidence of potential abuse, dependence, or withdrawal†

- **First and only**—nonscheduled prescription insomnia medication... not a controlled substance and can be prescribed for long-term use<sup>1</sup>
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle<sup>1</sup>
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies<sup>1</sup>
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression<sup>1</sup>
- **One simple 8-mg dose**<sup>1</sup>

†Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).<sup>1,2</sup>

Please visit [www.rozerem.com](http://www.rozerem.com)

 **Rozerem**<sup>TM</sup>  
**ramelteon** 8-mg tablets

*Proven for sleep.  
 Nonscheduled for added safety.*